X0306 4 2020-09-18 0 0001438533 Retrophin, Inc. RTRX 0001388773 Clague Laura C/O RETROPHIN, INC. 3721 VALLEY CENTRE DR., SUITE 200 SAN DIEGO CA 92130 0 1 0 0 Chief Financial Officer Common Stock 2020-09-18 4 A 0 3000 0.00 A 22473 D Common Stock 2020-09-22 4 S 0 1500 18.59 D 20973 D On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. /s/ Elizabeth E. Reed, Attorney-in-Fact 2020-09-22